# US 2023/0056856 A1 · Compositions and methods for tunable regulation of transcription

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0056856 A1
- Document ID: US20230056856A1
- Status: Published application
- Kind: A1
- Application number: 17/791,091
- Filed: 2021-01-08
- Published: 2023-02-23
- Earliest claimed: 2020-01-08
- Assignees: Obsidian Therapeutics, Inc.
- Applicants: Obsidian Therapeutics, Inc.
- Inventors: Vipin Suri; Mara Christine Inniss; Samantha Fleury
- Web page: https://patentgrep.com/patent/US20230056856A1

## CPC

- C07K 14/4702: {Regulators; Modulating activity}
- C12N 15/635: {Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline}
- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/15: Natural-killer [NK] cells; Natural-killer T [NKT] cells
- A61K 40/22: Immunosuppressive or immunotolerising
- A61K 40/416: {Antigens related to auto-immune diseases; Preparations to induce self-tolerance}
- A61K 40/42: Cancer antigens
- A61K 48/0066: {Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid}
- C07K 14/5434: {IL-12}
- C07K 14/721: {Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor}
- C12N 5/0638: {Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]}
- C12N 9/003: {Dihydrofolate reductase [DHFR] (1.5.1.3)}
- C12Y 105/01003: Dihydrofolate reductase (1.5.1.3)
- C12Y 301/04017: 3',5'-Cyclic-nucleotide phosphodiesterase (3.1.4.17)
- C12Y 402/01001: Carbonate dehydratase (4.2.1.1), i.e. carbonic anhydrase
- C12Y 502/01008: Peptidylprolyl isomerase (5.2.1.8), i.e. cyclophilin
- C07K 2319/20: containing a tag with affinity for a non-protein ligand
- C07K 2319/80: containing a DNA binding domain, e.g. Lacl or Tet-repressor
- C07K 2319/81: containing a Zn-finger domain for DNA binding
- C07K 2319/95: containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12Y: ENZYMES

## Abstract

The present disclosure provides compositions and methods related to transcription factor systems. Such systems provide for modular and tunable protein expression driven by regulated transcriptional activity.

## Claims

### Claim 1

(canceled)

### Claim 2

A modified cell comprising a first polynucleotide, said first polynucleotide comprising a first nucleic acid sequence that encodes a transcription factor activation domain; a second nucleic acid sequence that encodes a transcription factor DNA binding domain that binds to a specific polynucleotide binding site; and a third nucleic acid sequence that encodes a drug responsive domain (DRD);
wherein the transcription factor activation domain, the transcription factor DNA binding domain, or the combination of the transcription factor activation domain and the transcription factor DNA binding domain is operably linked to the DRD;
wherein the transcription factor activation domain and the transcription factor DNA binding domain interact to form a transcription factor that is able to activate transcription of a fourth nucleic acid sequence upon binding to the specific polynucleotide binding site; and
wherein the fourth nucleic acid sequence encodes a protein of interest and is operably linked to the specific polynucleotide binding site.

### Claim 3 (depends on 2)

The modified cell of claim 2, wherein the fourth nucleic acid sequence is operably linked to an exogenous inducible promoter comprising the specific polynucleotide binding site.

### Claim at position 4

4-6. (canceled)

### Claim 7 (depends on 2)

The modified cell of claim 2, wherein the transcription factor DNA binding domain is selected from the group consisting of c-Jun, FOXP3, ZFHD1, Cas9, Cas12, and TAL.

### Claim 8 (depends on 2)

The modified cell of claim 2, wherein the transcription factor activation domain is p65.

### Claim 9

(canceled)

### Claim 10

A modified cell comprising a polynucleotide comprising a first nucleic acid sequence encoding a drug responsive domain (DRD) and a second nucleic acid sequence encoding a transcription factor, wherein the transcription factor is operably linked to the DRD; and
wherein the transcription factor is able to bind to a specific polynucleotide binding site and activate transcription of a third nucleic acid sequence encoding a protein of interest, wherein the third nucleic acid sequence is operably linked to the specific polynucleotide binding site.

### Claim 11 (depends on 10)

The modified cell of claim 10, wherein the third nucleic acid sequence is operably linked to an exogenous inducible promoter comprising the specific polynucleotide binding site.

### Claim at position 10

12-14. (canceled)

### Claim 15 (depends on 10)

The modified cell of claim 10, wherein the DRD is derived from a parent protein selected from the group comprising: human carbonic anhydrase 2 (CA2), human DHFR, E. coli DHFR (ecDHFR), human estrogen receptor (ER), FKBP, human protein FKBP, and human PDE5.

### Claim 16 (depends on 10)

The modified cell of claim 10, wherein the DRD is stabilized in the presence of a ligand selected from the group consisting of Acetazolamide (ACZ), Methotrexate (MTX), and Trimethoprim (TMP).

### Claim at position 13

17-21. (canceled)

### Claim 22 (depends on 10)

The modified cell of claim 10, wherein the cell is a T cell, a natural killer cell (NK cell), or a tumor infiltrating lymphocyte (TIL).

### Claim at position 15

23-28. (canceled)

### Claim 29

A nucleic acid molecule comprising:
a. a first nucleic acid sequence encoding a transcription factor able to bind to a specific polynucleotide binding site and activate transcription; and
b. a second nucleic acid sequence encoding a drug responsive domain (DRD); wherein the transcription factor is operably linked to the DRD.

### Claim 30 (depends on 29)

The nucleic acid molecule of claim 29, further comprising:
c. a third nucleic acid sequence encoding a protein of interest, said third nucleic acid sequence being operably linked to an inducible promoter comprising the specific polynucleotide binding site.

### Claim 31 (depends on 29)

The nucleic acid molecule of claim 29, wherein the DRD is derived from a parent protein selected from the group comprising: human carbonic anhydrase 2 (CA2), human DHFR, ecDHFR, human estrogen receptor (ER), FKBP, human protein FKBP, and human PDE5.

### Claim 32 (depends on 29)

The nucleic acid molecule of claim 29, wherein the DRD is stabilized in the presence of a ligand selected from the group comprising: Acetazolamide (ACZ), Methotrexate (MTX), and Trimethoprim (TMP).

### Claim at position 20

33-37. (canceled)

### Claim 38 (depends on 29)

A vector comprising the nucleic acid molecule according to claim 29.

### Claim at position 22

39-50. (canceled)

### Claim 51

A method of producing a modified cell, said method comprising introducing into a cell a nucleic acid molecule comprising:
a. a first nucleic acid sequence that encodes a transcription factor DNA binding domain that binds to a specific polynucleotide binding site; and
b. a second nucleic acid sequence that encodes a drug responsive domain (DRD).

### Claim 52 (depends on 51)

The method of claim 51, wherein the nucleic acid molecule further comprises a third nucleic acid sequence that encodes a transcription factor activation domain.

### Claim 53 (depends on 52)

The method of claim 52, wherein either (i) the transcription factor DNA binding domain is operably linked to the DRD; (ii) the transcription factor activation domain is operably linked to the DRD; or (iii) the combination of the transcription factor DNA binding domain and the transcription factor activation domain is operably linked to the DRD.

### Claim 54 (depends on 53)

The method according to claim 53, further comprising introducing into the cell:
a fourth nucleic acid sequence encoding a protein of interest, said fourth nucleic acid sequence being operably linked to an inducible promoter comprising the specific polynucleotide binding site.

### Claim 55

(canceled)

### Claim 56 (depends on 54)

The method according to claim 54, wherein the fourth nucleic acid sequence is on the same nucleic acid molecule as the first, second and third nucleic acid sequences.

### Claim 57 (depends on 54)

The method according to claim 54, wherein the fourth nucleic acid sequence is on a different nucleic acid molecule than the first, second and third nucleic acid sequences.

### Claim at position 30

58-60. (canceled)

### Claim 61 (depends on 51)

The method according to claim 51, wherein the nucleic acid molecule is introduced into the cell by a plasmid or a viral vector.

### Claim 62

(canceled)

### Claim 63 (depends on 61)

The method according to claim 61, wherein the viral vector is selected from the group consisting of a lentivirus vector, a gamma retrovirus vector, adeno-associated virus (AAV) vector, adenovirus vector, and a herpes virus vector.

### Claim 64 (depends on 51)

The method according to claim 51, wherein the nucleic acid molecule is introduced into the cell by a non-viral delivery method.

### Claim 65 (depends on 51)

The method of claim 51, wherein the cell is a T cell, a natural killer cell (NK cell), or a tumor infiltrating lymphocyte (TIL).

### Claim at position 36

66-68. (canceled)

### Claim 69 (depends on 29)

A method for introducing a modified cell into a subject in need of disease treatment or prevention, the method comprising:
a. providing a population of cells;
b. introducing the nucleic acid molecule of claim 29 into at least one cell in the population of cells; and
c. delivering the cell into the subject.

### Claim at position 38

70-73. (canceled)

### Claim 74 (depends on 69)

The method according to claim 69, wherein the cell is a T cell, a natural killer cell (NK cell), or a tumor infiltrating lymphocyte (TIL).

### Claim at position 40

75-78. (canceled)

### Claim 79 (depends on 10)

The modified cell of claim 10, wherein the transcription factor comprises a DNA binding domain and wherein the DNA binding domain is selected from the group consisting of c-Jun, FOXP3, ZFHD1, Cas9, Cas12, and TAL.

### Claim 80 (depends on 10)

The modified cell of claim 10, wherein the transcription factor comprises a transcription factor activation domain comprising p65.

### Claim 81 (depends on 29)

The nucleic acid molecule of claim 29, wherein the transcription factor comprises a DNA binding domain and wherein the DNA binding domain is selected from the group consisting of c-Jun, FOXP3, ZFHD1, Cas9, Cas12, and TAL.

### Claim 82 (depends on 29)

The nucleic acid molecule of claim 29, wherein the transcription factor comprises a transcription factor activation domain comprising p65.
